Congratulations to Dr. David O’Reilly, Star PHD candidate and medical oncology trainee on his recent Young Investigator Award at ASCO (American Society of Clinical Oncology) on the 27th May, 2025.

Dr O’Reilly is clinical research fellow in the Beaumont RCSI Cancer Centre, with an interest in the development of novel liquid biopsy approaches in order to improve outcomes for patients with lung cancer.

David’s work on “Exhaled breath condensate tumour DNA analysis to predict progression on chemo-immunotherapy for patients with advanced non-small cell lung cancer” was selected from a prestigious group of global submissions and demonstrates a continued commitment to cancer research and progressing outcomes for patients with cancer.

This research is follows-on from research conducted as part of his PhD. During his PhD, the investigator led the ‘BRAND’ study, which investigated using exhaled breath samples to predict clinical benefit from treatment. The aim of his ASCO YIA award is specifically to investigate if exhaled breath liquid biopsy can be used to predict early progression on chemo-immunotherapy for patients with advanced non-small cell lung cancer.

The Conquer Cancer Young Investigator Award (YIA) aims to encourage and promote quality research in clinical oncology. Applicants are reviewed and evaluated by an independent selection committee. David is the only recipient of the award outside of North America this year.

Prof. Jarushka Naidoo, Professor of Medical Oncology here in Beaumont RCSI Cancer Centre, and research mentor to Dr. O’Reilly had this to say “Dr O’Reilly has received a very prestigious award from our foremost oncology society (ASCO- American society of clinical oncology), it’s Conquer Cancer Foundation Young Investigator Award. This is excellent news for Dr. O’Reilly and this is a real example of successful team science”.